The threat of terrorist attacks on civilians remains a significant concern for the populace and for those charged with their protection. Tetramethylenedisulfotetramine (TMDT) constitutes a significant threat. TMDT is a potent neurotoxic chemical that was available worldwide as a rodenticide until associated hazards led to discontinuance of its use. Although its production, sale, and use have been banned, it is widely available in the Peoples'Republic of China, and has been associated with numerous accidental and intentional poisonings. A severe poisoning in the U.S. was a subject of great attention by the CDC. TMDT has many characteristics that make it a desirable chemical for mass poisoning. Being a water soluble, odorless, and tasteless substance, it is ideally suited to use in adulteration of food and water. It is also stable and persistent in the environment, and can be cheaply and easily synthesized from readily available starting materials. It is acutely toxic, and has long-term effects. There is no known specific antidote to this agent. TMDT is a cage convulsant structurally related to picrotoxin and blocks the Cl- ionophore of the GABAA receptor complex as a mechanism of action. Our preliminary results indicate that TMDT induces a syndrome consisting of acute seizures (clonic and tonic- clonic) and seizure-related death and delayed seizures with lethal outcome. NMDA receptor antagonists (ketamine) better prevented lethal outcome compared to GABAA receptor potentiators (diazepam). Our hypothesis is that TMDT by binding to GABAA Receptor-Chloride Ionophore Complex blocks Cl- influx with consequent loss of membrane hyperpolarization, hyperexcitability of post-synaptic neurons, and sustained increases in [Ca2+]i.
Specific Aims to be determined:
Aim 1 : Establish and apply a cerebral neuronal culture screen to identify TMDT countermeasures. 1A. Measure TMDT-evoked changes in [Ca++]I in primary cerebral cortical cell cultures, and establish reliable, validated conditions for in vitro evaluation of candidate countermeasures for TMDT actions. 1B. Screen multiple agents from FDA-approved sedative- hypnotic-anticonvulsant-anesthetic and NMDA receptor antagonist classes, ranking them for their TMDT- antagonist activity.
Aim 2 : Examine short- and long-term effects of TMDT in an in vivo mouse model and test potential countermeasures against TMDT actions. 2A. Screen multiple agents from GABAAR agonist and NMDAR antagonist classes in vivo, ranking them for their TMDT-antagonist activity. 2B. Examine selected agents for protection against delayed TMDT toxicity. 2C. Determine re-challenge in the TMDT-induced syndrome. This research will result in straightforward in vitro screen test to reveal treatments effective against the TMDT syndrome. Ranking of this in vitro screen will be correlated to the ranking of efficacy of the drugs determined in the in vivo tests t confirm the validity. Results of our research will identify readily available therapies that treat short-term and prevent long-term toxicity, out of FDA-approved drugs. This will enhance medical response capabilities to TMDT exposure during an emergency.

Public Health Relevance

Tetramethylenedisulfotetramine (TMDT), a potent neurotoxic chemical, constitutes a significant threat since it is water soluble, odorless, and tasteless as wel as easy to obtain. TMDT induces seizures, status epilepticus, and seizure-related death, and there is no known specific antidote to this agent. We will systematically investigate FDA-approved drugs and their combination as well as experimental drugs in complementary in vitro and in vivo assays as TMDT antidotes. Results of our proposal will directly affect PHS and CDC recommendations regarding the therapeutic response to the TMDT threat.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21NS084900-01A1
Application #
8796530
Study Section
Special Emphasis Panel (ZRG1-MDCN-B (55))
Program Officer
Yeung, David
Project Start
2014-09-30
Project End
2016-07-31
Budget Start
2014-09-30
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$402,500
Indirect Cost
$152,500
Name
New York Medical College
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
041907486
City
Valhalla
State
NY
Country
United States
Zip Code
10595